Bioatla (BCAB) investor relations material

Executive summary

• Reported net income of $0.5 million for Q2 2026, reversing a net loss of $18.7 million in Q2 2025, primarily due to $6.5 million in revenue from a licensing amendment with Context Therapeutics.

• Operating expenses decreased significantly year-over-year due to workforce reductions and completion of Phase 2 trials.

• Company initiated a formal process to explore strategic options, including asset sales, licensing, or partnerships, and implemented a 70% workforce reduction in March 2026.

• Cash and cash equivalents were $1.5 million as of June 30, 2026, raising substantial doubt about the ability to continue as a going concern.

Financial highlights

• Q2 2026 revenue: $6.5 million (Q2 2025: $0.0 million), all from the Context Amendment.

• Research and development expenses: $3.3 million (Q2 2026), down from $13.7 million (Q2 2025).

• General and administrative expenses: $2.9 million (Q2 2026), down from $5.0 million (Q2 2025).

• Net income: $0.5 million (Q2 2026) vs. net loss of $18.7 million (Q2 2025).

• Cash used in operations for the first half of 2026: $5.7 million.

Outlook and guidance

• Company does not expect meaningful product revenue in the near future and anticipates continued operating losses.

• Expenses expected to decrease in the near term due to cost containment, but substantial additional capital will be required for future development.

• Ongoing strategic review may result in asset sales, partnerships, or other transactions, but outcomes are uncertain.